Liechti Lab

Psychedelics-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced the publication of its first data on the interaction of a selective serotonin uptake inhibitor, known as escitalopram, with an acute response to psilocybin in humans. The publication is based...